
The Femtech World Awards 2026, delivered in partnership with headline sponsor Planned Parenthood, celebrates the brightest lights in women's health innovation.
We will be celebrating some of the best examples of leadership, innovation and impact in key areas that affect women's health and wellbeing.
Key dates:
September 15 2025: Nominations/entries open
March 14 2026 Nominations/entries close
March 14 - April 2: Shortlisting and judging process
Late April: Winners announced during an online video presentation
Award categories
Research Project of the Year
sponsored by OncoGenomX
Women's Cancer Innovation
sponsored by Endomag
Menstrual Health Innovation
Premom
Cardiovascular Health Innovation
sponsored by Women as One
Startup of the Year
sponsored by Future Fertility
Fertility Innovation
sponsored by FinDBest IVF
Brain and Mental Health Innovation
sponsored by Women in Cloud
AI Innovation
sponsored by Women's Health Week
Menopause Innovation
sponsored by Cross Border Impact Ventures
Company of the Year
sponsored by Femovate
About the award
This award recognises an outstanding company that is driving innovation, impact and growth in the femtech.
The winner will be a company that has demonstrated exceptional leadership in addressing women’s health needs through groundbreaking products, services, or platforms.
The award celebrates organisations that are not only advancing women’s health but also shaping the future of global femtech.
About the sponsor
Femovate is a catalyst for change in women’s health.
We use design to fuel innovation across every stage of a woman’s health journey, from proactive prevention to early detection and personalised treatment.
As the global femtech incubator, we’ve invested over $2 million in design capital and work side-by-side with founding teams to launch market-ready solutions.
Collectively, the startups we support have raised $120 million, launched 30 products, and received 7 FDA clearances, with more clinical studies underway.
About the award
This award honours an individual or organisation pioneering the use of artificial intelligence to transform women’s health.
The winner will have demonstrated groundbreaking innovation in applying AI to improve diagnosis, treatment accessibility, or overall health outcomes for women.
This award celebrates those who are pushing the boundaries of AI to create a more inclusive, effective and equitable healthcare future for women.
About the sponsor
Women's health has been chronically overlooked, underserved, and underinvested. The market is at a tipping point.
With projections reaching $50B by 2025, women's health is no longer just a social imperative – it's a major business opportunity.
Our flagship women's health conferences across Europe and the USA unite the complete ecosystem - visionary founders, strategic investors, multinational corporations, and specialised service providers - accelerating life-changing solutions that address women's most critical unmet health needs.
About the award
This award celebrates a breakthrough product, service or initiative that is redefining menstrual health.
The winner will have demonstrated exceptional innovation in addressing the needs and challenges around menstruation, whether through technology, product design, education, accessibility, or destigmatisation.
This award recognises those driving meaningful change in how menstrual health is understood, supported and integrated into overall wellbeing.
About the sponsor
Premom is dedicated to helping women get pregnant quickly and naturally.
Unique and innovative ovulation prediction app - Premom is a simple, effective, and affordable solution for all women trying to conceive.
The app provides precision at your fingertips with a digital ovulation test reader, intelligent fertility charting, and customised cycle insights, streamlining your path to motherhood.
The sister company to Premom, easy@Home was the first brand in the USA to offer personalised testing solutions and devices and has become the first brand and largest volume seller of ovulation tests in the USA.
About the award
The winner of this award will have shown exceptional innovation in addressing the health, wellbeing and quality-of-life needs of people navigating perimenopause, menopause, and beyond.
Consideration will be given to impact, inclusivity accessibility, and the ability to break stigma while delivering meaningful solutions.
This award celebrates those leading the way in redefining how menopause is understood and supported across healthcare and society.
About the sponsor
Cross-Border Impact Ventures (CBIV) is an impact venture capital firm on a mission to revolutionise venture investing in health technology.
CBIV invests in early-growth stage health technology companies commercializing medical devices, diagnostics, therapeutics, and digital health innovations and leveraging cutting-edge technologies like Artificial Intelligence (AI) and Machine Learning (ML).
All innovations CBIV finances are relevant to women’s, children’s, and adolescents’ health and located in North America and Europe, with the ability to scale technologies to emerging markets.
CBIV is driven by the belief that good health should not be restricted by gender, age, race, wealth, or borders and seeks to expand access to their portfolio’s world class technologies inclusively and globally.
About the award
This award honours a groundbreaking innovation dedicated to the prevention, early detection treatment or ongoing care of cancers that uniquely or disproportionately affect women.
The winner will have demonstrated exceptional progress in advancing research, technology or patient-centred solutions that improve outcomes and quality of life.
This award celebrates those driving transformative change in the fight against women’s cancers.
About the sponsor
At Endomag, we believe everyone deserves a better standard of cancer care – that’s why we design our cancer localisation technologies with both the clinician and patient in mind.
Many leading hospitals across the world use our unique solutions to help breast cancer patients avoid surgery when it isn’t needed, and experience better outcomes when it is.
Our Magseed® marker is a tiny, non-radioactive seed, ideal for accurately marking tumours and lymph nodes, while the Magtrace® lymphatic tracer is the world’s first, long-lasting, non-radioactive dual tracer for lymphatic mapping.
Paired with the Sentimag® localisation platform, they have now been widely proven across over 200 clinical studies, featuring more than 20,000 patients.
About the award
This award recognises an outstanding innovation addressing brain and mental health challenges that uniquely or disproportionately impact women.
The winner will have demonstrated groundbreaking progress in areas such as mental wellbeing, neurological health, maternal mental health, cognitive care or stigma reduction.
This award honours those leading the way in advancing understanding, treatment, and support for women’s brain and mental health.
About the sponsor
Women In Cloud is a global network of 120,000 Women Tech Founders, Executives, Tech Professionals, and Allies in 80 countries who are committed to inspiring the tech ecosystem to be an inclusive force for change and take collective action by providing a powerful platform to collaborate, build community engagement and unlock $1B in new net economic access by 2030.
Through events and initiatives, Women In Cloud also promotes conversations arounds its focus areas of Cloud Workforce Development, Civic Engagement via Policy Advocacy, Entrepreneurship and Cloud/AI Innovation and Global partnerships with corporations, community leaders, and policy makers.
About the award
This award celebrates a pioneering product, service or initiative that is transforming fertility care and support.
The winner will have demonstrated exceptional innovation in helping individuals or couples navigate fertility journeys, whether through technology, treatments, education, accessibility, or emotional support.
Consideration will be given to scientific advancement, inclusivity, user impact, and the ability to break barriers in fertility health.
About the sponsor
FinDBest IVF is a global B2B digital platform created to simplify and accelerate how IVF and ART manufacturers connect with trusted, pre-vetted distributors around the world.
Launched in 2024, the platform addresses a long-standing challenge in the MedTech sector—fragmented, costly, and inefficient market access—by offering a curated, country-specific directory of active partners, complete with key segmentation, certification indicators, and direct contact tools.
From consumables and lab equipment to AI-powered embryo selection and genetic testing solutions, FinDBest makes it faster and easier for companies to scale internationally—without relying on expensive congresses or cold outreach.
About the award
This award recognises an outstanding research project that is advancing knowledge, innovation and impact in women’s health.
The winning project will have demonstrated excellence in scientific rigor, originality and potential to transform understanding, diagnosis or treatment of health issues affecting women.
This award recognises projects that are shaping the future of evidence-based care and creating pathways to better health outcomes for women.
About the sponsor
At OncogenomX Inc. we are dedicated to offering solutions and providing comprehensive support services that empower Drug Developers, Clinical Researchers, Oncologists,NextGenSeq Diagnostics Laboratories, NextGenSeq Service Organisations, Cancer Diagnostics and Therapeutics Companies to achieve their ambitious goals.
With a team of experienced professionals, we offer tailor-made solutions to help you navigate the complexities in your field of interest along the cancer care value chain with confidence.
Contact us to schedule a consultation and start your journey towards clinical success!
About the award
This award celebrates an early-stage company making a bold impact in women’s health through innovation, vision and execution.
The winning startup will have demonstrated strong potential to transform care, accessibility, or awareness in women’s health with a scalable solution.
Consideration will be given to innovation, market traction, inclusivity, impact and the ability to address unmet needs.
About the sponsor
Future Fertility is transforming fertility care with AI-powered solutions that close critical information gaps along the IVF journey.
Our clinically validated, non-invasive tools analyse oocyte images to predict each egg’s reproductive potential, supporting decision-making across key pathways: VIOLET™ for egg freezing, MAGENTA™ for IVF-ICSI, and ROSE™ for donor programmes and egg banks.
These reports deliver personalised insights into egg quality and ploidy potential, empowering patients and clinicians to make more informed decisions regarding next steps.
Today, Future Fertility’s technology is used in more than 230 clinics across 35+ countries.
Developed with the world’s largest oocyte image dataset linked to reproductive outcomes, our AI models generate quality scores that not only guide treatment planning and manage expectations, but also serve as objective, actionable KPIs for labs—driving improved outcomes and transparency in fertility care worldwide.
About the award
The Cardiovascular Health Innovation award recognises groundbreaking advances that are transforming women’s heart health and improving patient outcomes.
This award honours innovators at the forefront of progress in areas such as wearable monitoring, AI-driven diagnostics, breakthrough therapies, telehealth, and community-based care.
From improving early detection in women to enhancing quality of life and advancing equity for underserved populations, these achievements are redefining prevention, diagnosis, and treatment.
By celebrating this work, the award shines a spotlight on innovation that is saving lives today and shaping the future of women’s cardiovascular health.
About the sponsor
Women As One was founded in 2019 by Dr. Roxana Mehran and Dr. Marie-Claude Morice, two internationally recognised physicians in cardiovascular care and research.
The mission of the organisation is to promote talent in medicine by providing unique professional opportunities to women cardiologists.
These opportunities range from clinical education to research funding to mentorship and network building.
We also maintain a Talent Directory database, which includes comprehensive qualification data on nearly 3,000 women cardiologists across 15 cardiovascular subspecialties and over 100 countries worldwide.
Enter the Femtech World 2026 Awards now